BDSX News and Press, Biodesix Inc. From 05/11/23

2023-05-11 16:20:49 ET Biodesix press release ( NASDAQ: BDSX ): Q1 GAAP EPS of -$0.24 in-line. Revenue of $9.05M (+38.2% Y/Y) beats by $0.35M . For further details see: Biodesix GAAP EPS of -$0.24 in-line, revenue of $9.05M beats by $0.35M

First quarter 2023 Core Lung Diagnostic revenue of $8.6 million increased 86% over the comparable period in 2022; Record number of Core Lung Diagnostic tests delivered in Company history; Conference Call and Webcast Today at 4:30 p.m. ET Biodesix, Inc. (Nasdaq: BDSX)...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for first quarter ended March 31, 2023 after the close of trading on Thursday, May 11. Biodesix’s management will host a ...

2023-03-06 10:09:03 ET Biodesix, Inc. (BDSX) Q4 2022 Earnings Conference Call March 6, 2023 8:00 A.M. ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference C...

2023-03-06 06:02:15 ET Biodesix press release ( NASDAQ: BDSX ): Q4 GAAP EPS of -$0.35 misses by $0.07 . Revenue of $9.61M (+33.1% Y/Y) misses by $1.16M . 2023 Total Revenue Guidance Expected to be Between $52 Million and $55 Million - Mid-point of the range rep...

Fourth Quarter and Fiscal Year 2022 Core Lung Diagnostic Revenue of $8.2 Million and $29.3 Million Increased 51% and 57% over the comparable 2021 periods, respectively 2023 Total Revenue Guidance Expected to be Between $52 Million and $55 Million - Mid-point of the range represents growth...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will participate in a fireside chat and host in-person 1x1 investor meetings at Cowen’s 43rd Annual Heal...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2022 before the open of trading on Monday, March 6. Biodesix’s managem...

Summary Biodesix, Inc. published its Q3 financial results on November 3, 2022. The firm provides an array of lung cancer diagnostic tests in the U.S. Biodesix has obtained significant growth capital and signed an access contract with the V.A. and U.S. military medical centers. T...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced positive coverage decisions from four private payers including Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shie...